Sprint Bioscience AB
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PET… Read more
Sprint Bioscience AB (SPRINT) - Total Liabilities
Latest total liabilities as of September 2025: Skr15.37 Million SEK
Based on the latest financial reports, Sprint Bioscience AB (SPRINT) has total liabilities worth Skr15.37 Million SEK as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sprint Bioscience AB - Total Liabilities Trend (2011–2024)
This chart illustrates how Sprint Bioscience AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sprint Bioscience AB Competitors by Total Liabilities
The table below lists competitors of Sprint Bioscience AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
EVZ Ltd
AU:EVZ
|
Australia | AU$35.83 Million |
|
Eureka Homestead Bancorp Inc
PINK:ERKH
|
USA | $74.63 Million |
|
Youil Energy Technology Co. Ltd.
KQ:340930
|
Korea | ₩127.13 Billion |
|
Global Consumer Public Company Limited
BK:GLOCON
|
Thailand | ฿756.34 Million |
|
Brainzcompany Co. Ltd.
KQ:099390
|
Korea | ₩4.38 Billion |
|
Iep Invest
BR:IEP
|
Belgium | €17.15 Million |
|
Diagnostic Medical Systems SA
PA:ALDMS
|
France | €44.64 Million |
|
Lulu's Fashion Lounge Holdings Inc
NASDAQ:LVLU
|
USA | $100.82 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Sprint Bioscience AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.72 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sprint Bioscience AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sprint Bioscience AB (2011–2024)
The table below shows the annual total liabilities of Sprint Bioscience AB from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr32.78 Million | -5.26% |
| 2023-12-31 | Skr34.60 Million | +274.73% |
| 2022-12-31 | Skr9.23 Million | +6.35% |
| 2021-12-31 | Skr8.68 Million | -64.20% |
| 2020-12-31 | Skr24.25 Million | +194.82% |
| 2019-12-31 | Skr8.23 Million | -62.68% |
| 2018-12-31 | Skr22.05 Million | +198.09% |
| 2017-12-31 | Skr7.40 Million | -64.83% |
| 2016-12-31 | Skr21.03 Million | -18.54% |
| 2015-12-31 | Skr25.81 Million | +434.79% |
| 2014-12-31 | Skr4.83 Million | +17.47% |
| 2013-12-31 | Skr4.11 Million | +28.24% |
| 2012-12-31 | Skr3.20 Million | +329.45% |
| 2011-12-31 | Skr746.09K | -- |